Literature DB >> 15777289

Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively.

E Florvaag1, S G O Johansson, H Oman, L Venemalm, F Degerbeck, T Dybendal, M Lundberg.   

Abstract

BACKGROUND: Anaphylactic reactions to a neuromuscular blocking agent (NMBA) is more than six times as common in Norway as in Sweden, probably due to differences in preoperative sensitization. The prevalence of IgE-sensitization to morphine (MOR) and suxamethonium (SUX) in comparable populations in Bergen, Norway, and Stockholm, Sweden, was studied and related to possible sensitizing agents.
METHODS: Three hundred sera of 'allergics' and 500 blood donors in Bergen and Stockholm were tested for IgE antibodies to MOR and SUX using Pharmacia Diagnostics ImmunoCAP(Uppsala, Sweden) assay and the results compared to those of 65 patients from Bergen with documented anaphylaxis to NMBA. In addition, 84 different household chemicals were tested, by IgE antibody inhibition, for SUX and MOR.
RESULTS: In Norway 0.4% of blood donors, 3.7% of allergics and 38.5% of anaphylactics were IgE-sensitized to SUX, and 5.0, 10.0 and 66.7%, respectively, to MOR. No serum from Sweden was positive. The majority of those sensitized (69%) were women. Several household chemicals contained SUX and/or MOR activity, but the only difference between Norway and Sweden was cough mixtures containing pholcodine (PHO). IgE antibodies to PHO were present in 6.0% of blood donors from Norway and in no serum from Sweden. Of the anaphylactics, 65-68% were sensitized to MOR or PHO but only 39% to SUX.
CONCLUSIONS: IgE-sensitization to SUX, MOR and PHO was detected in Norway but not in Sweden. One possible explanation is the unrestricted use of cough mixtures containing MOR derivatives in Norway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15777289     DOI: 10.1111/j.1399-6576.2004.00591.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  20 in total

1.  Anaphylaxis with angioedema by rocuronium during induction of general anesthesia -A case report-.

Authors:  Won Ju Jeong; Woon Young Kim; Joo Hyung Son; Yoon-Sook Lee; Jae Hwan Kim; Young Cheol Park
Journal:  Korean J Anesthesiol       Date:  2010-04-26

Review 2.  Pediatric Patients with Previous Anaphylactic Reactions to General Anesthesia: a Review of Literature, Case Report, and Anesthetic Considerations.

Authors:  Manjiao Ma; Bo Zhu; Jing Zhao; Hongyi Li; Lian Zhou; Mu Wang; Xiuhua Zhang; Yuguang Huang
Journal:  Curr Allergy Asthma Rep       Date:  2020-04-22       Impact factor: 4.806

3.  IgE-mediated anaphylactic reactions to neuromuscular blocking agents: can they be prevented?

Authors:  E Florvaag; S G O Johansson
Journal:  Curr Allergy Asthma Rep       Date:  2008-09       Impact factor: 4.806

Review 4.  Perioperative anaphylaxis: what should be known?

Authors:  Pascale Dewachter; Claudie Mouton-Faivre; David L Hepner
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

5.  Is a positive history of non-anaesthetic drug allergy a predictive factor for positive allergy tests to anaesthetics?

Authors:  Natalia Hagau; Nadia Gherman-Ionica; Denisa Hagau; Sebastian Tranca; Manuela Sfichi; Dan Longrois
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

6.  Letter to the authors concerning the accepted manuscript: exploring the link between pholcodine and neuromuscular anaphylaxis by Brush et al.

Authors:  Astrid Uyttebroek; Julie Leysen; Chris Bridts; Didier Ebo
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

7.  Response to letter regarding article 'Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis'.

Authors:  Anna M Brusch; Russell C Clarke; Peter R Platt; Elizabeth Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 8.  Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis.

Authors:  Anna M Brusch; Russell C Clarke; Peter R Platt; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

9.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Authors:  Christine H Chung; Beloo Mirakhur; Emily Chan; Quynh-Thu Le; Jordan Berlin; Michael Morse; Barbara A Murphy; Shama M Satinover; Jacob Hosen; David Mauro; Robbert J Slebos; Qinwei Zhou; Diane Gold; Tina Hatley; Daniel J Hicklin; Thomas A E Platts-Mills
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 10.  The Developmental History of IgE and IgG4 Antibodies in Relation to Atopy, Eosinophilic Esophagitis, and the Modified TH2 Response.

Authors:  Rob C Aalberse; Thomas A Platts-Mills; Theo Rispens
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.